Headlines about Accuray (NASDAQ:ARAY) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Accuray earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 45.2584237638589 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Contrasting ABIOMED (ABMD) and Accuray (ARAY) (americanbankingnews.com)
- Accuray To Report Fiscal 2018 First Quarter Financial Results On October 24, 2017 (finance.yahoo.com)
- Traders Recap: Ansys, Inc., (NASDAQ:ANSS), Accuray Incorporated, (NASDAQ:ARAY) – Stocks In The News (press release) (tradingnewsnow.com)
- Is technical analysis on Accuray Incorporated (ARAY) is useful? – Wall Street Morning (wallstreetmorning.com)
- Accuray Incorporated (ARAY) Expected to Announce Quarterly Sales of $89.18 Million (americanbankingnews.com)
Shares of Accuray (NASDAQ ARAY) traded up 1.20% on Thursday, reaching $4.20. The company’s stock had a trading volume of 1,015,445 shares. Accuray has a 52-week low of $3.60 and a 52-week high of $6.00. The company’s market cap is $349.35 million. The company has a 50 day moving average price of $4.22 and a 200 day moving average price of $4.35.
Accuray (NASDAQ:ARAY) last released its earnings results on Tuesday, August 22nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.05). The firm had revenue of $112.09 million for the quarter, compared to the consensus estimate of $112.00 million. Accuray had a negative return on equity of 61.62% and a negative net margin of 7.71%. Accuray’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.09) EPS. On average, analysts anticipate that Accuray will post ($0.20) earnings per share for the current fiscal year.
A number of brokerages have recently weighed in on ARAY. BTIG Research reiterated a “hold” rating on shares of Accuray in a report on Thursday, August 24th. Zacks Investment Research upgraded Accuray from a “sell” rating to a “hold” rating in a report on Tuesday, September 19th. Jefferies Group LLC reiterated a “buy” rating and set a $7.00 price target on shares of Accuray in a report on Friday, June 30th. Royal Bank Of Canada restated a “hold” rating and issued a $5.00 target price on shares of Accuray in a research note on Thursday, August 24th. Finally, BidaskClub downgraded Accuray from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $6.00.
TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/10/12/accuray-aray-receives-media-sentiment-score-of-0-18.html.
In other news, COO Kelly Londy sold 99,136 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $4.24, for a total value of $420,336.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.91% of the stock is owned by company insiders.
Accuray Company Profile
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
What are top analysts saying about Accuray Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Accuray Incorporated and related companies.